← All People

Robert Chapkin

Chapkin, Robert
Robert Chapkin
CMAT 111
Undergraduate Education
B.Sc. University of Guelph, Canada (1981)
Graduate Education
M.Sc. University of Guelph, Canada (1983)
Ph.D. University of California, Davis (1986)
Postdoc. University of California, Davis School of Medicine (1986-88)
Joined Texas A&M in 1988

Stem cells, membrane biology and chronic disease prevention

Research in the Chapkin lab focuses on dietary/microbial modulators related to the prevention of cancer and chronic inflammatory diseases. Our central goal is to (1) understand cancer chemoprevention at a fundamental level, and (2) to test pharmaceutical agents in combination with dietary (countermeasures to the Western diet) to more effectively improve gut health and reduce systemic chronic inflammation.  Since diet influences gut microbiota composition and metabolite production, to unravel the interrelationships among gut health and the structure of the gut microbial ecosystem, we are in the process of evaluating (using transgenic mouse, Drosophila models and humans) how the gut microbiome modulates intestinal cells, innate immune cells and tumors.  As part of this endeavor, we are modeling, at the molecular level, the dynamic relationship between diet and gut microbe-derived metabolites which modulate chronic inflammation and the hierarchical cellular organization of the intestine, e.g., stem cell niche.  Work in the lab related to intestinal “phenotypic flexibility” falls into four specific areas:

  • Synergistic effects of systemic and lumenal metabolites on intestinal stem cells and differentiated colonocytes.
  • Development of novel noninvasive methodology using exfoliated cells (exfoliome) to monitor host/microbe interactions.
  • Effects of dietary/microbial bioactives on plasma membrane structure (proteolipid clustering) and function.
  • Investigation of the role of dietary and microbial ligands as modifiers of inflammation and colon cancer development.

Recent Publications

<!-- load from cache
  1. Salinas, ML, Fuentes, NR, Choate, R, Wright, RC, McMurray, DN, Chapkin, RS et al.. AdipoRon Attenuates Wnt Signaling by Reducing Cholesterol-Dependent Plasma Membrane Rigidity. Biophys. J. 2019; :.
    doi: 10.1016/j.bpj.2019.09.009. PubMed PMID:31630812. .

  2. Park, H, Jin, UH, Orr, AA, Echegaray, SP, Davidson, LA, Allred, CD et al.. Isoflavones as Ah Receptor Agonists in Colon-Derived Cell Lines: Structure-Activity Relationships. Chem. Res. Toxicol. 2019; :.
    doi: 10.1021/acs.chemrestox.9b00352. PubMed PMID:31621310. .

  3. Safe, S, Han, H, Goldsby, J, Mohankumar, K, Chapkin, RS. Aryl Hydrocarbon Receptor (AhR) Ligands as Selective AhR Modulators: Genomic Studies. Curr Opin Toxicol. ;11-12 :10-20.
    doi: 10.1016/j.cotox.2018.11.005. PubMed PMID:31453421. PubMed Central PMC6709982.

  4. Lampe, JW, Kim, E, Levy, L, Davidson, LA, Goldsby, JS, Miles, FL et al.. Colonic mucosal and exfoliome transcriptomic profiling and fecal microbiome response to a flaxseed lignan extract intervention in humans. Am. J. Clin. Nutr. 2019;110 (2):377-390.
    doi: 10.1093/ajcn/nqy325. PubMed PMID:31175806. PubMed Central PMC6669062.

  5. Torres-Adorno, AM, Vitrac, H, Qi, Y, Tan, L, Levental, KR, Fan, YY et al.. Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. Oncogene. 2019;38 (12):2135-2150.
    doi: 10.1038/s41388-018-0569-5. PubMed PMID:30459358. PubMed Central PMC6430703.

  6. Kim, E, Wright, GA, Zoh, RS, Patil, BS, Jayaprakasha, GK, Callaway, ES et al.. Establishment of a multicomponent dietary bioactive human equivalent dose to delete damaged Lgr5+ stem cells using a mouse colon tumor initiation model. Eur. J. Cancer Prev. 2019;28 (5):383-389.
    doi: 10.1097/CEJ.0000000000000465. PubMed PMID:30234553. PubMed Central PMC6422758.

  7. Erazo-Oliveras, A, Fuentes, NR, Wright, RC, Chapkin, RS. Functional link between plasma membrane spatiotemporal dynamics, cancer biology, and dietary membrane-altering agents. Cancer Metastasis Rev. 2018;37 (2-3):519-544.
    doi: 10.1007/s10555-018-9733-1. PubMed PMID:29860560. PubMed Central PMC6296755.

  8. Fuentes, NR, Mlih, M, Barhoumi, R, Fan, YY, Hardin, P, Steele, TJ et al.. Long-Chain n-3 Fatty Acids Attenuate Oncogenic KRas-Driven Proliferation by Altering Plasma Membrane Nanoscale Proteolipid Composition. Cancer Res. 2018;78 (14):3899-3912.
    doi: 10.1158/0008-5472.CAN-18-0324. PubMed PMID:29769200. PubMed Central PMC6050089.

  9. Triff, K, McLean, MW, Callaway, E, Goldsby, J, Ivanov, I, Chapkin, RS et al.. Dietary fat and fiber interact to uniquely modify global histone post-translational epigenetic programming in a rat colon cancer progression model. Int. J. Cancer. 2018;143 (6):1402-1415.
    doi: 10.1002/ijc.31525. PubMed PMID:29659013. PubMed Central PMC6105390.

  10. Jin, UH, Park, H, Li, X, Davidson, LA, Allred, C, Patil, B et al.. Structure-Dependent Modulation of Aryl Hydrocarbon Receptor-Mediated Activities by Flavonoids. Toxicol. Sci. 2018;164 (1):205-217.
    doi: 10.1093/toxsci/kfy075. PubMed PMID:29584932. PubMed Central PMC6016704.

Search PubMed